The historical rank and industry rank for Predictive Oncology's Gross Margin % or its related term are showing as below:
POAI'
s Gross Margin % Range Over the Past 10 Years
Min: 53.52 Med: 64.32 Max: 77.4
Current: 64.33
During the past 13 years, the highestGross Margin % of Predictive Oncology was 77.40%. The lowest was 53.52%. And the median was 64.32%.
POAI's Gross Margin % is ranked better than 67.84% of 796
companies
in the Medical Devices & Instruments industry
Industry Median: 53.575
vs POAI: 64.33
Predictive Oncology had a gross margin of 25.97% for the quarter that ended in Dec. 2023 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for Predictive Oncology was -0.70% per year.
Predictive Oncology Gross Margin % Historical Data
The historical data trend for Predictive Oncology's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Predictive Oncology's Gross Margin %
For the Medical Instruments & Supplies subindustry, Predictive Oncology's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Predictive Oncology's Gross Margin % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Predictive Oncology's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Predictive Oncology had a gross margin of 25.97% for the quarter that ended in Dec. 2023 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Predictive Oncology Gross Margin % Related Terms
Thank you for viewing the detailed overview of Predictive Oncology's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Predictive Oncology (Predictive Oncology) Business Description
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
POAI has been successfully added to your 